Lymph-node-targeted, mKRAS-specific amphiphile vaccine in pancreatic and colorectal cancer: the phase 1 AMPLIFY-201 trial.

"additional details are provided in the study protocol (supplementary data 1 ).; reporting summary supplementary data 1 trial protocol extended data extended data fig 1 study schema."

"Competing interests S.P. reports clinical research funding to institution from Arqule, Bristol Myers Squibb, Eli Lilly, Elicio Therapeutics, Holy Stone Healthcare, Ipsen, Mirati Therapeutics, Novartis, Rgenix, Sanofi-Aventis, Xencor, Astellas, Framewave, 4D Pharma, Boehringer Ingelheim, NGM Biopharmaceuticals, Janssen, Arcus Biosciences, BioNTech, Zymeworks and Pfizer. S.P. also reports consultant/advisory fees from Zymeworks, Ipsen, Novartis, Janssen and Boehringer Ingelheim. Z.A.W. has received consultant/advisory fees from Lilly Oncology, AstraZeneca, Merck, Daiichi Sankyo, Macrogenics, Amgen, Bristol Myers Squibb, Astellas, Ipsen, Arcus, Novartis, Roche, Seagen and Pfizer and has received research funding (institutional) from Elicio Therapeutics, Arcus, Plexxikon, Novartis and Merck. C.D.W. reports research funding from Elicio Therapeutics, Novartis, Actuate Therapeutics, Merck, AstraZeneca and Mirati and advisory board relationships with Ipsen, Actuate Therapeutics and Genentech. M.F. has received research funding (institutional) from AstraZeneca, Bristol Myers Squibb, Eli Lilly, Merck, Novartis, Pfizer, Roche, Genmab, Elicio Therapeutics, Mirati, Amgen, Replimmune, Checkmate Pharmaceuticals, Gilead, GlaxoSmithKline, Immunocore, Seagen, Tesaro and Abbvie and has been on advisory boards for Abbvie, Beigene, Jazz Pharmaceuticals, Mirati and AstraZeneca. P.M.K. reports a consultancy/advisory board relationship with Elicio (scientific advisory board member/stock ownership); consultancy/advisory board relationships with Guardant Health, Illumina, Natera, Foundation Medicine, Daichi Sankyo, Tempus, Bayer, MSD Oncology/Merck, Delcath Systems, QED Therapeutics, Taiho Oncology (self/institution), Exact Sciences, Eisai, BostonGene, Neogenomics, Saga Diagnostics, Servier, Seagen, Eli Lilly and Ipsen (to institution); and research funding/trial support from Merck (to institution), Novartis (to institution), Agenus Bio (to institution), Boston Scientific (to institution), Tersera (to institution) and Advanced Accelerator Applications as well as a travel grant for IIT from AstraZeneca. C.E.D. reports research funding from Elicio Therapeutics. A.D.L. reports institutional contracts with Elicio Therapeutics, Bristol Myers Squibb, Exelixis, Arrys Therapeutics, Hutchison Medipharma, Corcept Therapeutics, Conjupro Biotherapeutics and AbbVie for trials where she is the local principal investigator. She serves as Pancreatic Cancer/Neuroendocrine Co-Chair on the Elsevier ClinicalPath Oncology Committee. V.C. has held a consulting or advisory role at Ispen, Gristone Oncology, Westwood Bioscience and Apeiron Biologics; he has been on the speakers’ bureau for Ipsen and Celgene; and he has received research funding from Elicio Therapeutics, Roche and Merck. O.B. reports no relevant disclosures. H.V., L.M.S., A.M.T., J.R.P., E.W., L.K.M., P.C.D., T.K. and C.M.H. are current or former employees of Elicio Therapeutics and, as such, receive salary and benefits, including ownership of stock and stock options, from the company. L.K.M., P.C.D. and C.M.H. have amphiphile vaccine patents pending to Elicio Therapeutics. E.M.O. reports relationships with Rafael Therapeutics (DSMB); Seagen, Boehringer Ingelheim, BioNTech, Ipsen, Merck, Silenseed, Novartis, AstraZeneca, BioSapien, Thetis and Autem, Tempus (consulting/advisory relationship); Agios, Genentech/Roche, Eisai, Zymeworks (spouse: consulting/advisory relationship); and Genentech/Roche, Celgene/Bristol Myers Squibb, BioNTech, AstraZeneca, Arcus, Elicio Therapeutics, Parker Institute, Pertzye and NCI/NIH (research funding)."

"The study was sponsored and funded by Elicio Therapeutics. We thank the patients and their caregivers and families for their participation in this study; the physicians, nurses and site staff who cared for the patients and supported the study; and D. M. Lidgate for expert medical writing assistance. Employees of Elicio Therapeutics received salaries for their contributions to the study. Aside from grants to their institutions, no other authors received specific funding for this work."